







> 60 mm P-value
Nr of patients 5252 4558 1565 544
Basic characteristics
Age, years 63.612.1 63.111.9 63.011.9 64.011.5 0.07
Male gender, % 74.4 77.6 78.9 82.0 <0.001
Total stent lengths, mm 15.42.9 27.64.3 48.45.7 82.018.7 <0.001
DAPT at baseline, % 72.3 73.5 74.6 73.4 0.26
1-year outcome
All death, % 1.56% 1.65% 1.98% 2.02% 0.63
Cardiac death, % 0.97% 1.10% 1.34% 1.29% 0.61
MI, % 1.43% 1.58% 2.05% 1.29% 0.35
CD-TLR, % 1.26% 1.27% 2.30% 1.65% 0.01
TVF, % 3.66% 3.73% 5.50% 5.33% 0.003
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neous coronary intervention (PCI) with drug-eluting stents (DES)
contribute to risk of subsequent death. Yet, the impact of the timing of
these events on subsequent mortality is less well understood.
METHODS ADAPT-DES was a large, prospective, multicenter registry
designed to identify the predictors of stent thrombosis. Patients
with successful PCI had assessment of platelet function and were
followed for 2 years. Events occurring after PCI – deﬁnite or probable
stent thrombosis (ST), myocardial infarction (MI) not related to
ST, and major bleeding (MB) were classiﬁed as early (30 days),
late (31-365 days) or very late (>365 days). Death within 12 months
of the events was analyzed by Kaplan-Meier techniques and a
Cox regression multivariable model was constructed to analyze the
relationship between each event – as a time-updated variable and
mortality.
RESULTS Among 8,582 patients, 294 had MI not related to ST (3.4%),
75 had ST (0.9%), 691 had MB (8.1%) and 7,522 had no event (87.6%)
during follow-up. Subsequent death within 2 years occurred in 12.4%
27.2%, 10.5%, and 2.7% of these patients respectively, P<0.0001. The
independent predictors of death were: increasing age, male sex, in-
sulin-requiring diabetes mellitus, MI before index PCI (>7 days),
chronic kidney disease, cigarette smoking, higher white blood cell
count, lower hemoglobin and lack of dual antiplatelet therapy (time-
adjusted). The time-adjusted relationship between these events
(corrected for the other events) and subsequent death, according to
the time of their occurrence, appears in the Table (reference
population is the group of patients without a particular event in the
speciﬁed time frame). High-platelet reactivity (HPR) and
presentation with acute coronary syndrome at index PCI were not
independent predictors of death, but HPR was highly predictive of
ST (P¼0.001), MI (P¼0.0006) and MB (P¼0.002).
CONCLUSIONS In an all-comers patient population treated with
DES, MI, ST and MB within 2 years are not uncommon (w1 in 8 pa-
tients). Early ST and early MI increased substantially the risk of
death, while MB had a less pronounced effect, emphasizing
the importance of improved devices, drugs and technique to prevent
their occurrence.Event typeHR [95%CI] for death after event occurrence according to event timingAny time £30 days 31 - 365 days >365 daysST 12.03 [8.05,
17.97]569.60 [197.36,
1643.89]8.33 [4.12, 16.83] 5.41 [2.39, 12.26]MI (no-ST) 2.00 [1.35, 2.94] 12.65 [1.47,
108.93]2.51 [1.37, 4.60] 3.22 [1.96, 5.28]MB 2.23 [1.71, 2.92] 2.80 [0.90, 8.68] 5.41 [3.75, 7.81] 2.82 [1.91, 4.17]CATEGORIES CORONARY: PCI Outcomes
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BACKGROUND Long coronary lesions have been associated with
worse clinical outcomes. Our aim was to assess one-year clinical
outcomes in real-world patients with different length of lesions after
implantation of bioresorbable polymer drug eluting stent (DES).
METHODS We analyzed data of unselected patients who received
Nobori Biolimus A9 eluting stent within the large, prospective,
single-arm, multicentre e-NOBORI registry. The primary endpoint
was target lesion failure (TLF) deﬁned as composite of cardiac
death, target vessel related myocardial infarction (MI) and clinically
driven target lesion revascularization at 1-year. An independent
clinical events committee adjudicated all endpoint related adverse
events.
RESULTS A total of 11919 patients were included in the analysis, of
which 44.1%, 38.2%, 13.1% and 4.6% had stent lesion  20mm,
20-40mm, 40-60mm and >60mm, respectively. The mean age did not
differ across four subgroups. There were more male patients with
increased lesion length across groups (Table). The proportion of
diabetic patients (33.2 %, 31.4%, 32.5%, 36.8%, P¼0.036),
hypertensive patients (71.0%, 70.5%, 73.3%, and 75.7, p¼0.021) and
current smokers (26.7%, 27.6%, 26.4% and 21.6%, P¼0.038) werealso different across subgroups. Other basic characteristics such as
previous MI and pervious stroke did not differ (p0.21). LAD was
the most frequent (45.2%) target vessel in stent lesion  20 mm
group, while RCA was the most frequent (41.1%) target vessel in
stent lesion > 60mm group. Complex lesion type (B2þC) were
45.4%, 59.6%, 62.6% and 65.7% across the groups. Total number of
lesions treated per patient were 1.71.6, 2.01.3, 2.61.4 and
3.51.9 respectively (P<0.01). Number of stents per lesion were
1.10.3, 1.20.4, 1.30.5 and 1.50.8 (p<0.01) respectively. There
were no differences in diameter stenosis at baseline (on average
84.8%, p¼0.60) while after procedure they were 2.8%, 2.9%, 1.9%
and 2.6% (P<0.01) respectively. At 1 year, there was no difference
(P>0.35) in the rate of any death, cardiac death, and MI (Table).
Composite endpoints TLF was slightly higher in long lesion
subgroups (2.9%, 3.4%, 4.7% and 4.2% respectively, p¼0.005). The
rate of stent thrombosis was low and comparable across 4
subgroups (0.38%, 0.55%, 0.77% and 0.18%, p¼0.16).CONCLUSIONS In a real-life practice registry, patients with long
lesions showed favorable and similar clinical outcomes when treated
with Nobori Biolimus A9 eluting stent. Although we cannot
completely exclude the possibility of underreporting of events,
especially of periprocedural MIs, the comparable and very low rate of
stent thrombosis across different lesion length groups up to 1 year is
encouraging.
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BACKGROUND We investigated whether non-invasive discrimination
of chronic total occlusion (CTO), a complete interruption of coronary
artery ﬂow, and subtotal occlusion (STO), a functional total occlusion,
is feasible using coronary computed tomography angiography (CTA).
CTO and STO may be different in pathophysiology and clinical treat-
ment strategy.
METHODS We included 486 consecutive patients (median age 63
years, male gender 82%) who showed a total of 553 completely
occluded coronary arteries in coronary CTA. The length of occlusion,
side branches, the shape of proximal stump, and collateral vessels
were measured as anatomical ﬁndings. Transluminal attenuation
gradient (TAG), which reﬂects intraluminal contrast kinetics and
functional extent of collateral ﬂow, was measured as a physiological
surrogate. All patients were followed by invasive coronary angiog-
raphy (CAG).
RESULTS Coronary arteries with CTO showed longer occlusion
length (cutoff 15 mm), higher TAG distal (cutoff  -0.9 HU/10mm),
more frequent side branches, blunted stump, cross-sectional
B28 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5calciﬁcation 50%, and collateral vessels compared to arteries with
STO (p<0.001, all). Combination of these ﬁndings could distinguish
CTO from STO (c-statistics¼0.88 (95% CI¼0.94–0.90),
sensitivity¼83%, speciﬁcity¼77%, positive predictive value (PPV)¼
55%, negative predictive value (NPV)¼93%, p<0.001). Percutaneous
coronary intervention (PCI) was attempted in 342 arteries and was
successful in 279 arteries (82%). CT ﬁndings could predict the un-
successful PCI (c-statistics¼0.70 (0.65–0.75), sensitivity¼63%, specif-
icity¼73%, PPV¼91%, NPV¼31%, p<0.001).
CONCLUSIONS Non-invasive coronary CT angiography could discern
chronic total occlusion from subtotal occlusion, and also could predict
the success of attempted PCI.
CATEGORIES IMAGING: Non-Invasive
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BACKGROUND Previous studies have shown that high and low
platelet reactivity (HPR and LPR respectively) are associated with
adverse events following percutaneous coronary intervention (PCI),
however, therapy windows were not consistent in different studies.
We aimed to determine the optimal cutoff value of platelet reactivity
to prevent major adverse events (MACE) and bleeding in eastern Asian
PCI patients.
METHODS Consecutive 6266 non-emergent PCI patients with aspirin
and clopidogrel therapy were enrolled prospectively in the single-
center, large-volume investigation from January to December 2013.
Platelet reactivity (ADP-induced platelet-ﬁbrin clot strength
[MAADP]) was determined by thrombelastography. MACE and
Bleeding Academic Research Consortium (BARC) classiﬁcation2
bleeding were assessed between different categories of platelet reac-
tivity and Syntax Score (SS).
RESULTS Overall, 475 MACE and 152 major bleeding (BARC grade2)
events were recorded during one year follow-up. With receiver
operating characteristic (ROC) curve, we determined the cutoff values
of MAADP for MACE and major bleeding (45 mm and 34mm, respec-
tively). Then, patients were classiﬁed according to MAADP (>45 mm,
34–45 mm, and <34 mm) and we evaluated the impact of platelet
reactivity on MACE and major bleeding in different Syntax Score
subgroups (SS<15 and SS15) with multivariable Cox survival anal-
ysis. In low SS group, MAADP>45 mm was the predictor of MACE (HR:
2.3; 95%CI: 1.6-5.9), but MAADP<34 mm did not show signiﬁcant
predicting value for major bleeding (HR: 1.3; 95%CI: 0.4-8.1). In high
SS group, MAADP>45 mm was still the predictor of MACE (HR: 2.6;
95%CI: 1.3-6.3), while MAADP<34 mm show signiﬁcant impact on
major bleeding (HR: 1.8; 95%CI: 1.2-4.7).
CONCLUSIONS Platelet reactivity measured by thrombelastography
could predict MACE and major bleeding in elective PCI patients,
especially in those with high SS. Therapy window of anti-platelet
drugs is narrow in eastern Asian population and further studies on
tailored treatment of high-risk patients are needed.
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BACKGROUND Drug-eluting stents (DES) reduce angiographic reste-
nosis and enhance event-free survival compared with bare-metalstents after implantation in coronary arteries. Limitations of current
DES remain stent thrombosis and neo-atherosclerosis related to
impaired healing, and repeat revascularization due to (late-) in-
stent-restenosis. Endothelial repair can be substantially enhanced
by CD34þ endothelial progenitor cells. The Combo stent combines a
CD34þ antibody layer to attract endothelial progenitor cells, and
thus promotes stent healing, with the abluminal release of sirolimus
to prevent neointima formation and restenosis. The aim of this
registry is to evaluate the long term safety and performance of the
abluminal sirolimus coated bio-engineered stent in routine clinical
practice.
METHODS The multicenter, prospective, clinical outcomes after
deployment of the abluminal sirolimus coated bio-engineered stent
post market registry, the REMEDEE Registry, is an international
registry to evaluate outcomes in an all-comers population of patients
undergoing percutaneous coronary intervention with (attempted)
Combo stent placement in the setting of routine clinical care. Base-
line demographic, clinical, and angiographic data, as well as follow-
up data up to ﬁve years will be obtained. Clinical endpoints are
deﬁned as a composite of cardiac death, non-fatal myocardial
infarction (MI) not clearly attributable to a non-target vessel, or
target lesion revascularization (TLR) (percutaneous or by coronary
artery bypass grafting (CABG)) in consecutive patients undergoing
percutaneous coronary intervention with (attempted) Combo stent
placement. All events will be adjudicated by an independent Clinical
Events Committee. Cumulative event rates are estimated by a
Kaplan-Meier model.
RESULTS A total of 1000 patients were included in 9 European sites
between June 2013 and March 2014, of which 30.4% patients pre-
senting with acute coronary syndrome (ACS) (17.8% ST-segment
elevation myocardial infarction). Mean age was 6511 years, 73.9% of
patients are male. 184 (18.4%) patients are diabetic, 25.3% of patients
have had a previous myocardial infarction, 6.8% had previous CABG.
The primary endpoint of one year target lesion failure will be available
at the TCT conference 2015.
CONCLUSIONS This is the ﬁrst multicenter, prospective, non-inter-
ventional trial evaluating the long term clinical outcomes of patients
treated with a Combo stent.
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BACKGROUND The incidence, predictors, and prognostic impact of
post-discharge bleeding (PDB) after percutaneous coronary interven-
tion (PCI) with drug-eluting stent (DES) implantation are unclear. This
study sought to characterize the determinants and consequences of
PDB after PCI.
METHODS The incidence and predictors of clinically relevant
bleeding events occurring within 2 years following hospital
discharge were assessed from the prospective Assessment of Dual
Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) study.
